Clinical Trial Update: AZD9833 China PK Study [Phase 1]

View source ↗

Summary

AstraZeneca's AZD9833 Phase 1 pharmacokinetic study in China for estrogen receptor–positive, HER2-negative metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• AZD9833 (AZD9833)

Snippet

Sponsor: AstraZeneca | Conditions: ER+, HER2-, Metastatic Breast Cancer | Phase 1 | Status: COMPLETED